|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
|  |

 |

 |
|

|  |  |  |  |
| --- | --- | --- | --- |
|

|  |  |  |
| --- | --- | --- |
|

|  |
| --- |
| Community Pharmacy England logo |

|  |
| --- |
| Newsletter2nd February 2024 |

 |

 |

 |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| The voice of community pharmacy (banner) |

 |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| **This newsletter - sent on Mondays, Wednesdays and Fridays - contains important information and resources to support community pharmacies across England.** |

 |

 |
|

|  |
| --- |
|  |

 |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| In this update: GPhC safety provision guidance; New valproate safety materials; Price concessions update; MHRA Class 4 update |

 |

 |
|

|  |
| --- |
|  |

 |
|

|  |
| --- |
|  |

 |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| The General Pharmaceutical Council (GPhC) has released advice for pharmacy owners and superintendents on safely implementing pharmacy services following the start of the Pharmacy First Service across England. This advice comes amidst persistent pressures and demands on community pharmacy services, as well as the growing suite of services offered by pharmacy teams.The GPhC has emphasised the importance of regular assessments of staffing levels and skill mix to prioritise patient safety, to ensure that there are sufficient staff members who are equipped with the required training, knowledge, and skills to deliver all pharmacy services safely and effectively. |

 |

 |
|

|  |
| --- |
| [**Read more, including the full guidance**](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=a7c60f0481&e=d19e9fd41c)  |

 |
|

|  |
| --- |
|  |

 |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| MHRA issues new materials for valproate safety measuresThe Medicines and Healthcare products Regulatory Agency (MHRA) has released new safety and educational materials to support the implementation of regulatory measures for valproate-containing products.These measures aim to reduce known risks, such as harm to babies during pregnancy and impaired fertility in males. The materials include updated guides, acknowledgment forms, patient cards, posters, and warning stickers.Pharmacy owners are encouraged to put in place a plan to implement the first phase of [new regulatory measures,](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=992ccc9b90&e=d19e9fd41c) which came into force on 31st January 2024.[Find out more](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=0f23aee63c&e=d19e9fd41c) |

 |

 |
|

|  |
| --- |
|  |

 |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| Rolled over price concessions for February 2024We have released a list of price concessions granted in January that have been confirmed as eligible to roll over to February 2024.Since May 2023, the Department of Health and Social Care (DHSC) implemented a process to roll over certain concessionary prices to the following month. This is part of the ongoing review of the price concession setting system for community pharmacies, which was agreed upon in the Year 4 and 5 (2022/23 and 2023/24) funding settlement deal. Since the [announcement](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=3cc3fc365b&e=d19e9fd41c) of this, Community Pharmacy England has been working closely with DHSC to improve this system.[Read more and view the list of rolled over price concessions](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=f2553cf9eb&e=d19e9fd41c) |

 |

 |

|  |  |
| --- | --- |
|

|  |
| --- |
|  |

 |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| Class 4 Medicines Defect Information: Gepretix 100mg Capsules (Exeltis UK Limited)Exeltis UK Limited has informed the MHRA regarding an inconsistency in the Patient Information Leaflet (PIL) packaged in cartons of the specified batches of Gepretix 100mg capsules.[Learn more](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=119e2ac993&e=d19e9fd41c)  |

 |

 |
|

|  |
| --- |
|  |

 |
|

|  |
| --- |
| Community Pharmacy England banner |

 |
|

|  |
| --- |
|  |

 |

 |
|

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| Twitter |

 |

 |

 |

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| Facebook |

 |

 |

 |

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| LinkedIn |

 |

 |

 |

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| Website |

 |

 |

 |

 |

 |

 |

 |

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| **Community Pharmacy England**Address: 14 Hosier Lane, London EC1A 9LQTel: 0203 1220 810 | Email: comms.team@cpe.org.ukCopyright © 2024 Community Pharmacy England, All rights reserved.You are receiving this email because you are subscribed to our newsletters. Please note Community Pharmacy England is the operating name of the Pharmaceutical Services Negotiating Committee (PSNC). |

 |

 |

 |

 |

 |

